BrainStorm Cell Therapeutics Prepares for Upcoming Financial Call
BrainStorm Cell Therapeutics Upcoming Financial Conference Call
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing adult stem cell therapies for neurodegenerative diseases, is set to announce its financial results for the year. A conference call and webcast have been scheduled to discuss the fourth quarter and the annual results, aiming to provide shareholders with crucial updates.
Details of the Call
The call is scheduled for March 31, 2025, at 8:30 AM Eastern Time. During this session, Chaim Lebovits, President and Chief Executive Officer of BrainStorm, will lead the discussion. Joining him will be Dr. Hartoun Hartounian, the Chief Operating Officer, Dr. Bob Dagher, the Chief Medical Officer, and Alla Patlis, the interim Chief Financial Officer. This team will share insights on the financial performance and future directions of the company.
Submit Questions in Advance
Participants in the investment community are encouraged to submit their questions prior to the call. This advance preparation allows for a more structured and informative session. Questions need to be submitted by 10:00 AM Eastern Time on March 28, 2025.
Joining the Call
Investors can join the call using the following telephone numbers: For U.S. participants, please dial 888-506-0062. International calls can be made at 973-528-0011. The access code for the call is 508970. The call will also be available via a webcast for broader accessibility.
Replay Information
For those who cannot attend the live session, a replay will be available. The replay can be accessed using the numbers shared above. U.S. listeners can call 877-481-4010, while international listeners may dial 919-882-2331. The replay will remain available until April 14, 2025, for anyone who wishes to catch up on what was discussed.
About BrainStorm Cell Therapeutics Inc.
BrainStorm stands at the forefront of developing advanced therapies aimed at treating debilitating neurodegenerative conditions. The company utilizes both autologous and allogeneic approaches to create innovative solutions. Moreover, BrainStorm enjoys exclusive global licensing rights for the NurOwn technology platform, which facilitates the production of autologous MSC-NTF cells, recognized for their potential in treating amyotrophic lateral sclerosis (ALS).
The NurOwn platform has received Orphan Drug designations from both the U.S. FDA and the European EMA, further corroborating its significance. BrainStorm is preparing to initiate a confirmatory Phase 3b trial of NurOwn, aiming to reinforce safety and efficacy claims. Additionally, their novel exosome technology, derived from MSC-NTF cells, presents an allogeneic therapeutic platform tailored to achieve targeted delivery of bioactive molecules, enhancing treatment effectiveness in neurodegenerative and respiratory diseases.
Looking Forward
As BrainStorm continues to evolve, it has successfully concluded a Phase 3 trial assessing NurOwn in ALS and is advancing other clinical studies for progressive multiple sclerosis (MS). Support for these initiatives has been bolstered by grants from esteemed organizations like the California Institute for Regenerative Medicine (CIRM) and the National MS Society (NMSS).
Contact Information
If you have inquiries about the conference call or the company’s initiatives, you can reach out to Michael Wood at +1 646-597-6983. He is available to provide information regarding the upcoming event or any other inquiries about BrainStorm Cell Therapeutics Inc.
Frequently Asked Questions
When is the financial results announcement scheduled?
The financial results announcement for BrainStorm Cell Therapeutics Inc. is set for March 31, 2025.
How can I submit questions for the conference call?
Questions can be submitted via email before the submission deadline of 10:00 AM Eastern Time on March 28, 2025.
What number do I call to join the conference call?
You can call 888-506-0062 for U.S. participants and 973-528-0011 for international participants. Use the access code 508970.
Is there a replay available for the conference call?
Yes, a replay will be available until April 14, 2025. The toll-free replay number is 877-481-4010 for U.S. listeners.
What technologies does BrainStorm specialize in?
BrainStorm specializes in innovative therapies for neurodegenerative diseases, utilizing both autologous and allogeneic platforms, particularly their NurOwn technology.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
